[go: up one dir, main page]

TWI717629B - Cyp17抑制劑的藥物組合物及其製備方法 - Google Patents

Cyp17抑制劑的藥物組合物及其製備方法 Download PDF

Info

Publication number
TWI717629B
TWI717629B TW107129767A TW107129767A TWI717629B TW I717629 B TWI717629 B TW I717629B TW 107129767 A TW107129767 A TW 107129767A TW 107129767 A TW107129767 A TW 107129767A TW I717629 B TWI717629 B TW I717629B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
composition according
cyclodextrin
active ingredient
cellulose
Prior art date
Application number
TW107129767A
Other languages
English (en)
Chinese (zh)
Other versions
TW201912162A (zh
Inventor
王捷
王偉
錢雯
張鳳娥
Original Assignee
大陸商江蘇恒瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恒瑞醫藥股份有限公司 filed Critical 大陸商江蘇恒瑞醫藥股份有限公司
Publication of TW201912162A publication Critical patent/TW201912162A/zh
Application granted granted Critical
Publication of TWI717629B publication Critical patent/TWI717629B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
TW107129767A 2017-08-28 2018-08-27 Cyp17抑制劑的藥物組合物及其製備方法 TWI717629B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201710750827 2017-08-28
??201710750827.8 2017-08-28
CN201710750827.8 2017-08-28
CN201710758825 2017-08-29
??201710758825.3 2017-08-29
CN201710758825.3 2017-08-29
CN201810205415 2018-03-13
CN201810205415.0 2018-03-13
??201810205415.0 2018-03-13

Publications (2)

Publication Number Publication Date
TW201912162A TW201912162A (zh) 2019-04-01
TWI717629B true TWI717629B (zh) 2021-02-01

Family

ID=65524928

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107129767A TWI717629B (zh) 2017-08-28 2018-08-27 Cyp17抑制劑的藥物組合物及其製備方法

Country Status (3)

Country Link
CN (1) CN110636837B (fr)
TW (1) TWI717629B (fr)
WO (1) WO2019042247A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CN111617257A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种阿比特龙或其衍生物药物组合物及其应用
AU2020240017A1 (en) * 2019-03-18 2021-11-04 AustinPx, LLC Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
CN118873509A (zh) * 2020-03-18 2024-11-01 西藏海思科制药有限公司 口服药物组合物
CN113750032B (zh) * 2020-06-01 2024-07-16 成都海博为药业有限公司 一种口服的阿比特龙药物组合物及其制备方法及用途
WO2022042645A1 (fr) * 2020-08-26 2022-03-03 上海博志研新药物技术有限公司 Composition orale à libération prolongée d'édaravone, procédé de préparation et application
WO2022103639A1 (fr) 2020-11-16 2022-05-19 Orcosa Inc. Méthodes de traitement de maladies auto-immunes ou inflammatoires avec du cannabidiol ou ses dérivés/analogues
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN118234742A (zh) * 2021-12-01 2024-06-21 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途
CN115684514B (zh) * 2022-11-24 2024-04-26 则正(济南)生物科技有限公司 评价仿制药和原研药生物利用度的方法及其应用
CN118141941B (zh) * 2024-03-07 2024-12-20 深圳市宇健生物医药有限公司 含醋酸阿比特龙的药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133416A1 (en) * 2012-05-04 2015-05-14 Jagotec Ag Pharmaceutical Composition Comprising Abiraterone Acetate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186412B2 (en) * 2008-08-18 2015-11-17 Entera Bio Ltd. Methods and compositions for oral administration of insulin
WO2013012959A1 (fr) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Nouvelles compositions et procédés de traitement du cancer de la prostate
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
EP2793896A4 (fr) * 2011-12-22 2015-06-24 Tokai Pharmaceuticals Inc Méthodes et compositions pour la polythérapie à l'aide d'inhibiteurs de p13k/mtor
CN103446069A (zh) * 2012-05-29 2013-12-18 重庆医药工业研究院有限责任公司 一种阿比特龙的口服固体组合物及其制备方法
CA2885193C (fr) * 2012-09-17 2021-04-27 Bind Therapeutics, Inc. Procede de preparation de nanoparticules therapeutiques
PT2897620T (pt) * 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
CN102961358B (zh) * 2012-11-29 2017-08-04 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙液体胶囊
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
CN105267224B (zh) * 2014-07-06 2018-05-18 天津金耀集团有限公司 一种醋酸阿比特龙的药物组合物
WO2017037647A1 (fr) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Compositions pharmaceutiques stables d'abiratérone
CN106539765A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 一种醋酸阿比特龙片及其制备方法
CN105535979B (zh) * 2015-11-22 2019-06-25 李素华 一种提高难溶药物生物利用度的自微乳化载药系统及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133416A1 (en) * 2012-05-04 2015-05-14 Jagotec Ag Pharmaceutical Composition Comprising Abiraterone Acetate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmaceutics 2018, 10, 134; doi:10.3390/pharmaceutics10030134 *

Also Published As

Publication number Publication date
WO2019042247A1 (fr) 2019-03-07
CN110636837A (zh) 2019-12-31
CN110636837B (zh) 2022-05-24
TW201912162A (zh) 2019-04-01

Similar Documents

Publication Publication Date Title
TWI717629B (zh) Cyp17抑制劑的藥物組合物及其製備方法
JP5220746B2 (ja) 制御放出システム及びその製造方法
JP2006514688A5 (fr)
US7923026B2 (en) Embedded micellar nanoparticles
CN105828806A (zh) 制剂
CN101495096A (zh) 纳米微粒泊沙康唑制剂
CN101259106A (zh) 含有头孢菌素的纳米控释组合物
CN101171000A (zh) 包含环孢菌素的毫微粒和控制释放组合物
CN101262860A (zh) 纳米微粒对乙酰氨基酚制剂
IL197701A (en) A solid composition containing nanotubes and a process for making them
JP2009541359A (ja) ナノ粒子状ナプロキセンおよび制御放出ヒドロコドンを含む組成物
WO2019155416A2 (fr) Composition pharmaceutique stable d'anti-androgènes non stéroïdiens faiblement solubles
US12521352B2 (en) Taste masking drug formulations
US20150342893A1 (en) Celecoxib formulations useful for treating colorectal cancer
BRPI0515815B1 (pt) forma medicamentosa de multipartículas contendo substâncias ativas de ácido nucléico formuladas mucoadesivas, bem como seu processo de preparação
JP2009543803A (ja) モダフィニルのナノ粒子製剤
WO2018108157A1 (fr) Composition pharmaceutique à libération prolongée / contrôlée de rucaparib pour la voie orale, et utilisation de cette dernière
CN109394685B (zh) 一种vegfr抑制剂的药物组合物及其制备方法
Kasashima et al. Oral sustained-release suspension based on a lauryl sulfate salt/complex
CN111617258A (zh) 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
KR20080047509A (ko) 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
CN101287453A (zh) 包含头孢菌素的毫微粒和控制释放组合物
CN111617257A (zh) 一种阿比特龙或其衍生物药物组合物及其应用
CN106727382A (zh) 一种卡维地洛过饱和自微乳分散片及其制备方法
US20080206348A1 (en) Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees